The role of properdin in zymosan- and Escherichia coli-induced complement activation

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2606-2613

  Harboe, Morten ^a   Garred, Peter ^b   Lindstad, Julie K ^a   Pharo, Anne ^a   Müller, Fredrik ^c   Stahl, Gregory L ^d   Lambris, John D ^e   Mollnes, Tom E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF OSLO   (Norway)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; C3 INHIBITING PEPTIDE COMPSTATIN[26-29]; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; EGTAZIC ACID; MAGNESIUM ION; MANNOSE BINDING LECTIN; PROPERDIN; PROTEIN INHIBITOR; SPHINGOLIPID ACTIVATOR PROTEIN 2; UNCLASSIFIED DRUG; ZYMOSAN;

ANTIGEN RECOGNITION; ARTICLE; BACTERIAL STRAIN; CELL STIMULATION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; MEMBRANE RECONSTITUTION; MICROTITER PLATE ASSAY; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SOLID;

ADULT; COMPLEMENT PATHWAY, ALTERNATIVE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HUMANS; MALE; NEUTROPHILS; PROPERDIN; PROTEIN BINDING; SUBSTRATE SPECIFICITY; ZYMOSAN;

EID: 84865413613     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200269     Document Type: Article

References (62)

1. Pillemer, L., L. Blum, I. H. Lepow, O. A. Ross, E. W. Todd, and A. C. Wardlaw. 1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120: 279-285.
2. Spitzer, D., L. M. Mitchell, J. P. Atkinson, and D. E. Hourcade. 2007. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179: 2600-2608.
3. Ecker, E. E. 1958. Louis Pillemer; 1908-1957. J. Immunol. 80: 415-416.
4. Lepow, I. H. 1980. Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, properdin, and scientific controversy. J. Immunol. 125: 471-475.
5. Lachmann, P. 2006. Complement before molecular biology. Mol. Immunol. 43: 496-508.
6. Kimura, Y., T. Miwa, L. Zhou, and W. C. Song. 2008. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 111: 732-740.
7. Stover, C. M., J. C. Luckett, B. Echtenacher, A. Dupont, S. E. Figgitt, J. Brown, D. N. Männel, and W. J. Schwaeble. 2008. Properdin plays a protective role in polymicrobial septic peritonitis. J. Immunol. 180: 3313-3318.
8. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway revisited. J. Cell. Mol. Med. 12: 1074-1084.
9. Kemper, C., J. P. Atkinson, and D. E. Hourcade. 2010. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 28: 131-155.
10. Medicus, R. G., O. Götze, and H. J. Müller-Eberhard. 1976. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 144: 1076-1093.
11. Pangburn, M. K., and H. J. Müller-Eberhard. 1986. The C3 convertase of the alternative pathway of human complement: enzymic properties of the bimolecular proteinase. Biochem. J. 235: 723-730.
12. Fearon, D. T., and K. F. Austen. 1975. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142: 856-863.
13. Fearon, D. T. 1979. Activation of the alternative complement pathway. CRC Crit. Rev. Immunol. 1: 1-32.
14. Hourcade, D. E. 2006. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281: 2128-2132.
15. Kemper, C., L. M. Mitchell, L. Zhang, and D. E. Hourcade. 2008. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc. Natl. Acad. Sci. USA 105: 9023-9028.
16. Ferreira, V. P., C. Cortes, and M. K. Pangburn. 2010. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology 215: 932-940.
17. Krarup, A., S. Thiel, A. Hansen, T. Fujita, and J. C. Jensenius. 2004. L-ficolin is a pattern recognition molecule specific for acetyl groups. J. Biol. Chem. 279: 47513-47519.
18. Garred, P., C. Honoré, Y. J. Ma, S. Rørvig, J. Cowland, N. Borregaard, and T. Hummelshøj. 2010. The genetics of ficolins. J. Innate Immun. 2: 3-16.
19. Gout, E., V. Garlatti, D. F. Smith, M. Lacroix, C. Dumestre- Pérard, T. Lunardi, L. Martin, J. Y. Cesbron, G. J. Arlaud, C. Gaboriaud, and N. M. Thielens. 2010. Carbohydrate recognition properties of human ficolins: glycan array screening reveals the sialic acid binding specificity of M-ficolin. J. Biol. Chem. 285: 6612-6622.
20. Harboe, M., P. Garred, M. S. Borgen, G. L. Stahl, A. Roos, and T. E. Mollnes. 2006. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin. Exp. Immunol. 144: 512-520.
21. Suankratay, C., X. H. Zhang, Y. Zhang, T. F. Lint, and H. Gewurz. 1998. Requirement for the alternative pathway as well as C4 and C2 in complementdependent hemolysis via the lectin pathway. J. Immunol. 160: 3006-3013.
22. Brouwer, N., K. M. Dolman, R. van Zwieten, E. Nieuwenhuys, M. Hart, L. A. Aarden, D. Roos, and T. W. Kuijpers. 2006. Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop. Mol. Immunol. 43: 2051-2060.
23. Zhao, H., N. Wakamiya, Y. Suzuki, M. T. Hamonko, and G. L. Stahl. 2002. Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. Hybrid. Hybridomics 21: 25-36.
24. Harboe, M., G. Ulvund, L. Vien, M. Fung, and T. E. Mollnes. 2004. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138: 439-446.
25. Harboe, M., P. Garred, E. Karlstrøm, J. K. Lindstad, G. L. Stahl, and T. E. Mollnes. 2009. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol. 47: 373-380.
26. Sahu, A., B. K. Kay, and J. D. Lambris. 1996. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157: 884-891.
27. Mallik, B., M. Katragadda, L. A. Spruce, C. Carafides, C. G. Tsokos, D. Morikis, and J. D. Lambris. 2005. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J. Med. Chem. 48: 274-286.
28. Janssen, B. J., E. F. Halff, J. D. Lambris, and P. Gros. 2007. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282: 29241-29247.
29. Magotti, P., D. Ricklin, H. Qu, Y. Q. Wu, Y. N. Kaznessis, and J. D. Lambris. 2009. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J. Mol. Recognit. 22: 495-505.
30. Hourcade, D. E. 2008. Properdin and complement activation: a fresh perspective. Curr. Drug Targets 9: 158-164.
31. Collard, C. D., A. Väkevä, M. A. Morrissey, A. Agah, S. A. Rollins, W. R. Reenstra, J. A. Buras, S. Meri, and G. L. Stahl. 2000. Complement activation after oxidative stress: role of the lectin complement pathway. Am. J. Pathol. 156: 1549-1556.
32. Fung, M., P. G. Loubser, A. Undar, M. Mueller, C. Sun, W. N. Sun, W. K. Vaughn, and C. D. Fraser, Jr. 2001. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J. Thorac. Cardiovasc. Surg. 122: 113-122.
33. Mollnes, T. E., T. Lea, S. S. Frøland, and M. Harboe. 1985. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22: 197-202.
34. Seelen, M. A., A. Roos, J. Wieslander, T. E. Mollnes, A. G. Sjöholm, R. Wurzner, M. Loos, F. Tedesco, R. B. Sim, P. Garred, et al. 2005. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 296: 187-198.
35. Harboe, M., O. Closs, L. J. Reitan, and P. Draper. 1981. Demonstration of antibodies reacting with different determinants on Mycobacterium leprae antigen 7. Int. J. Lepr. Other Mycobact. Dis. 49: 147-158.
36. Laursen, I., G. Houen, P. Højrup, N. Brouwer, L. B. Krogsøe, L. Blou, and P. R. Hansen. 2007. Second-generation nanofiltered plasma-derived mannanbinding lectin product: process and characteristics. Vox Sang. 92: 338-350.
37. Garred, P., F. Larsen, H. O. Madsen, and C. Koch. 2003. Mannose-binding lectin deficiency: revisited. Mol. Immunol. 40: 73-84.
38. Larsen, F., H. O. Madsen, R. B. Sim, C. Koch, and P. Garred. 2004. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J. Biol. Chem. 279: 21302-21311.
39. Larsson, K., K. Wester, P. Nilsson, M. Uhlén, S. Hober, and H. Wernérus. 2006. Multiplexed PrEST immunization for high-throughput affinity proteomics. J. Immunol. Methods 315: 110-120.
40. Persson, A., S. Hober, and M. Uhlén. 2006. A human protein atlas based on antibody proteomics. Curr. Opin. Mol. Ther. 8: 185-190.
41. Hopp, T. P., and K. R. Woods. 1981. Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. USA 78: 3824-3828.
42. Mollnes, T. E., T. Lea, M. Harboe, and J. Tschopp. 1985. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand. J. Immunol. 22: 183-195.
43. Mollnes, T. E., H. Redl, K. Høgåsen, A. Bengtsson, P. Garred, L. Speilberg, T. Lea, M. Oppermann, O. Götze, and G. Schlag. 1993. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 91: 295-300.
44. Hein, E., C. Honoré, M. O. Skjoedt, L. Munthe-Fog, T. Hummelshøj, and P. Garred. 2010. Functional analysis of Ficolin-3 mediated complement activation. PLoS ONE 5: e15443.
45. Kjaer, T. R., A. G. Hansen, U. B. Sørensen, O. Nielsen, S. Thiel, and J. C. Jensenius. 2011. Investigations on the pattern recognition molecule M-ficolin: quantitative aspects of bacterial binding and leukocyte association. J. Leukoc. Biol. 90: 425-437.
46. Thomsen, T., A. Schlosser, U. Holmskov, and G. L. Sorensen. 2011. Ficolins and FIBCD1: soluble and membrane bound pattern recognition molecules with acetyl group selectivity. Mol. Immunol. 48: 369-381.
47. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
48. Lappegård, K. T., D. Christiansen, A. Pharo, E. B. Thorgersen, B. C. Hellerud, J. Lindstad, E. W. Nielsen, G. Bergseth, D. Fadnes, T. G. Abrahamsen, et al. 2009. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. USA 106: 15861-15866.
49. Harboe, M., E. B. Thorgersen, and T. E. Mollnes. 2011. Advances in assay of complement function and activation. Adv. Drug Deliv. Rev. 63: 976-987.
50. Phillips, A. E., J. Toth, A. W. Dodds, U. V. Girija, C. M. Furze, E. Pala, R. B. Sim, K. B. Reid, W. J. Schwaeble, R. Schmid, et al. 2009. Analogous interactions in initiating complexes of the classical and lectin pathways of complement. J. Immunol. 182: 7708-7717.
51. Lachmann, P. J., and L. Halbwachs. 1975. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. 21: 109-114.
52. Pangburn, M. K., R. D. Schreiber, and H. J. Müller-Eberhard. 1981. Formation of the initial C3 convertase of the alternative complement pathway: acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 154: 856-867.
53. Pangburn, M. K., and H. J. Müller-Eberhard. 1983. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann. N. Y. Acad. Sci. 421: 291-298.
54. Bexborn, F., P. O. Andersson, H. Chen, B. Nilsson, and K. N. Ekdahl. 2008. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol. Immunol. 45: 2370-2379.
55. Xu, W., S. P. Berger, L. A. Trouw, H. C. de Boer, N. Schlagwein, C. Mutsaers, M. R. Daha, and C. van Kooten. 2008. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J. Immunol. 180: 7613-7621.
56. Sahu, A., A. M. Soulika, D. Morikis, L. Spruce, W. T. Moore, and J. D. Lambris. 2000. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J. Immunol. 165: 2491-2499.
57. Dimitrova, P., N. Ivanovska, W. Schwaeble, V. Gyurkovska, and C. Stover. 2010. The role of properdin in murine zymosan-induced arthritis. Mol. Immunol. 47: 1458-1466.
58. Kimura, Y., L. Zhou, T. Miwa, and W. C. Song. 2010. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J. Clin. Invest. 120: 3545-3554.
59. Camous, L., L. Roumenina, S. Bigot, S. Brachemi, V. Frémeaux- Bacchi, P. Lesavre, and L. Halbwachs-Mecarelli. 2011. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117: 1340-1349.
60. Wirthmueller, U., B. Dewald, M. Thelen, M. K. Schäfer, C. Stover, K. Whaley, J. North, P. Eggleton, K. B. Reid, and W. J. Schwaeble. 1997. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J. Immunol. 158: 4444-4451.
61. Agarwal, S., C. A. Specht, H. Haibin, G. R. Ostroff, S. Ram, P. A. Rice, and S. M. Levitz. 2011. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio 2: e00178-11.
62. Pagano, M. B., H. F. Zhou, T. L. Ennis, X. Wu, J. D. Lambris, J. P. Atkinson, R. W. Thompson, D. E. Hourcade, and C. T. Pham. 2009. Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation 119: 1805-1813.